Study of novel FSGS compound

Restricted access

A new study called FirstX is now enrolling participants and will examine a compound called CXA-10 in primary FSGS as a first-line drug for people who would normally have been treated with high-dose steroids. CXA-10 is in a class of oral compounds called nitrated fatty acids. It is a signaling agent with anti-inflammatory/immunomodulatory, antifibrotic, antioxidative, and other properties that are important in the pathobiology of FSGS, according to an abstract for the trial presented during ASN Kidney Week 2018.

Primary FSGS is often treated with steroids, but side effects of prolonged use may include obesity, hypertension, growth impairment, diabetes, and